Carbohydrate and Domain Architecture of an Immature Antibody Glycoform Exhibiting Enhanced Effector Functions
Max Crispin,Thomas A. Bowden,Charlotte H. Coles,Karl Harlos,A. Radu Aricescu,David J. Harvey,David I. Stuart,E. Yvonne Jones;Max Crispin;Thomas A. Bowden;Charlotte H. Coles;Karl Harlos;A. Radu Aricescu;David J. Harvey;David I. Stuart;E. Yvonne Jones;
Journal of molecular biology2009Vol. 387pp. 1061-1066
174
jones2009journalcarbohydrate
Abstract
Antibodies contain a conserved glycosylation site that has emerged as a target for the modulation of antibody effector functions. The crystal structure of a biosynthetic intermediate of human IgG1, bearing immature oligomannose-type glycans and reported to display increased antibody-dependent cellular cytotoxicity, demonstrates that glycan engineering can bias the Fc to an open conformation primed for receptor binding.